Research Analysts Offer Predictions for NKTR Q2 Earnings

Nektar Therapeutics (NASDAQ:NKTR) – Analysts at Zacks Research upped their Q2 2026 earnings per share estimates for Nektar Therapeutics in a report released on Thursday, September 4th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings of ($3.05) per share for the quarter, up from their prior estimate of ($3.26). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q3 2026 earnings at ($4.72) EPS, Q4 2026 earnings at ($4.64) EPS, FY2026 earnings at ($15.25) EPS, Q1 2027 earnings at ($3.42) EPS, Q2 2027 earnings at ($3.52) EPS and FY2027 earnings at ($18.26) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($2.95) EPS for the quarter, beating the consensus estimate of ($3.13) by $0.18. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%.The business had revenue of $11.18 million for the quarter, compared to analyst estimates of $9.42 million.

Several other equities analysts have also commented on the company. Wall Street Zen lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. HC Wainwright upped their price target on Nektar Therapeutics to $120.00 and gave the company a “buy” rating in a research note on Tuesday, June 24th. William Blair reaffirmed a “market perform” rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. B. Riley upped their price target on Nektar Therapeutics from $60.00 to $85.00 and gave the company a “buy” rating in a research note on Tuesday, July 8th. Finally, BTIG Research increased their target price on Nektar Therapeutics from $60.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.33.

Nektar Therapeutics Stock Up 11.7%

Shares of Nektar Therapeutics stock opened at $40.18 on Monday. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $40.45. The business’s fifty day simple moving average is $25.78 and its 200-day simple moving average is $16.37. The firm has a market cap of $764.22 million, a PE ratio of -4.57 and a beta of 1.05.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at about $130,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Nektar Therapeutics in the 1st quarter valued at about $41,000. Wellington Management Group LLP raised its position in Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 49,319 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in Nektar Therapeutics by 267.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 175,193 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 127,459 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Nektar Therapeutics by 23.3% in the 1st quarter. Rhumbline Advisers now owns 221,761 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 41,948 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Insider Transactions at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 1,573 shares of the stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $26.59, for a total transaction of $41,826.07. Following the transaction, the chief executive officer owned 69,340 shares of the company’s stock, valued at approximately $1,843,750.60. This represents a 2.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders sold 4,959 shares of company stock worth $138,917. 3.71% of the stock is currently owned by corporate insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.